Short Interest in Athira Pharma, Inc. (NASDAQ:ATHA) Drops By 18.5%

Athira Pharma, Inc. (NASDAQ:ATHA) was the recipient of a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 1,810,000 shares, a decline of 18.5% from the November 15th total of 2,220,000 shares. Based on an average daily volume of 4,750,000 shares, the days-to-cover ratio is currently 0.4 days. Currently, 5.1% of the shares of the stock are short sold.

Athira Pharma Stock Up 0.5 %

Shares of ATHA traded up $0.00 during trading hours on Friday, reaching $0.58. The company’s stock had a trading volume of 373,474 shares, compared to its average volume of 1,583,835. The company has a 50 day moving average of $0.58 and a two-hundred day moving average of $1.71. Athira Pharma has a 1-year low of $0.41 and a 1-year high of $4.30. The firm has a market cap of $22.62 million, a price-to-earnings ratio of -0.21 and a beta of 2.99.

Athira Pharma (NASDAQ:ATHA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.05. As a group, analysts forecast that Athira Pharma will post -2.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on ATHA shares. Rodman & Renshaw downgraded Athira Pharma from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 4th. BTIG Research downgraded shares of Athira Pharma from a “buy” rating to a “neutral” rating in a research note on Wednesday, September 4th. JMP Securities lowered Athira Pharma from an “outperform” rating to a “market perform” rating in a research report on Wednesday, September 4th. Finally, Mizuho downgraded Athira Pharma from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $5.00 to $0.50 in a research note on Thursday, September 19th.

Hedge Funds Weigh In On Athira Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. Rothschild Investment LLC acquired a new position in shares of Athira Pharma during the 2nd quarter worth approximately $34,000. XTX Topco Ltd bought a new position in Athira Pharma in the 2nd quarter valued at approximately $60,000. Invst LLC acquired a new stake in Athira Pharma in the second quarter valued at $68,000. American Century Companies Inc. lifted its position in shares of Athira Pharma by 9.4% in the 2nd quarter. American Century Companies Inc. now owns 38,940 shares of the company’s stock worth $103,000 after purchasing an additional 3,333 shares during the period. Finally, Forefront Analytics LLC lifted its stake in shares of Athira Pharma by 126.0% in the 2nd quarter. Forefront Analytics LLC now owns 46,595 shares of the company’s stock valued at $123,000 after purchasing an additional 25,979 shares during the period. Institutional investors own 57.12% of the company’s stock.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.